CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cambrex Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cambrex Corporation
1 Meadowlands Plaza
Phone: (201) 804-3000p:201 804-3000 East Rutherford, NJ  07073-2150  United States Fax: (201) 804-9852f:201 804-9852
This company was Merged or Acquired on 12/4/2019.
This company ceased filing statements with the SEC on 12/16/2019.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
---YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
--YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2869 Industrial organic chemicals, not elsewhere classified
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board ShlomoYanai 66 4/24/2014 11/29/2012
President, Chief Executive Officer, Director Steven M.Klosk 62 5/14/2008 10/1/1992
Chief Financial Officer, Executive Vice President, Corporate Development and Strategy Gregory P.Sargen 53 9/4/2018 2/1/2003
8 additional Officers and Directors records available in full report.

Business Names
Business Name
AS Cambrex Tallinn
Avista Pharma Solutions
Cambrex Charles City, Inc.
11 additional Business Names available in full report.

General Information
Number of Employees: 1,732 (As of 12/31/2018)
Outstanding Shares: 33,724,367 (As of 9/30/2019)
Shareholders: 22,572
Stock Exchange: NYSE
Federal Tax Id: 222476135
Fax Number: (201) 804-9852
Email Address: Annemarie.Hess@cambrex.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 19, 2024